Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus- Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients.

Published byΚαλλιόπη Τρικούπης Modified over 5 years ago

Similar presentations

Presentation on theme: "A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus- Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients."— Presentation transcript:

1 A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus- Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses  Pooja Khandelwal, Tsuyoshi Fukuda, Kana Mizuno, Ashley Teusink-Cross, Parinda A. Mehta, Rebecca A. Marsh, Angela D.M. Kashuba, Alexander A. Vinks, Stella M. Davies  Biology of Blood and Marrow Transplantation  Volume 22, Issue 10, Pages (October 2016) DOI: /j.bbmt Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Representative example demonstrating CCR5 expression as observed on flow cytometry histograms and functional blockade of CCR5 with addition of maraviroc. (A1) Shows CCR5 expression in a healthy control patient. (A2) Shows the internalization of CCR5 expression with the addition of CCL5. (A3) Shows the preservation of CCR5 expression with addition of maraviroc, despite addition of CCL5. (B1) Shows the pretransplantation CCR5 expression of a patient on study. (B2) Shows the internalization of CCR5 expression with the addition of CCL5. (C1) Shows the expression of CCR5 on day 0 and day +14 after stem cell transplantation. Patient is currently on maraviroc. (C2) Shows the preservation of CCR5 expression despite addition of CCL5. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Pharmacokinetic profiles on day 0 and day +10 in 13 patients normalized to a dose of 300 mg/m2. Mean ± standard deviation shown. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Percentage of internalization of CCR5 in the presence of CCL5 observed before transplantation, day 0, and day +14 in 13 patients on maraviroc. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus- Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients."

Similar presentations

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
Serial Profile of Vitamins and Trace Elements during the Acute Phase of Allogeneic Stem Cell Transplantation  Yasuhito Nannya, Akihito Shinohara, Motoshi.

Serial Profile of Vitamins and Trace Elements during the Acute Phase of Allogeneic Stem Cell Transplantation  Yasuhito Nannya, Akihito Shinohara, Motoshi.
Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus– Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation.

Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus– Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation.
Peripheral Blood Expansion of CD38 Bright CD8+ Effector Memory T-Cells Predicts Acute Graft Versus Host Disease with a Diagnostic Accuracy of 87%  Pooja.

Peripheral Blood Expansion of CD38 Bright CD8+ Effector Memory T-Cells Predicts Acute Graft Versus Host Disease with a Diagnostic Accuracy of 87%  Pooja.
Phase 1 Study of Maraviroc As Acute Graft-Versus-Host Disease Prophylaxis in Pediatrics  Pooja Khandelwal, MD, Tsuyoshi Fukuda, PhD, Ashley Teusink, PharmD,

Phase 1 Study of Maraviroc As Acute Graft-Versus-Host Disease Prophylaxis in Pediatrics  Pooja Khandelwal, MD, Tsuyoshi Fukuda, PhD, Ashley Teusink, PharmD,
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Vaccination of Children following Allogeneic Stem Cell Transplantation

Vaccination of Children following Allogeneic Stem Cell Transplantation
Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.

Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.
Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.
Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.

Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.
Allogeneic Stem Cell Transplantation in Myelofibrosis

Allogeneic Stem Cell Transplantation in Myelofibrosis
Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease
Vitamin A Deficiency Is Associated with Increased Risk of Acute Graft Versus Host Disease in Children  Dana T. Lounder, MD, Sonata Jodele, MD, Pooja Khandelwal,

Vitamin A Deficiency Is Associated with Increased Risk of Acute Graft Versus Host Disease in Children  Dana T. Lounder, MD, Sonata Jodele, MD, Pooja Khandelwal,
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Eculizumab Treatment Improves Survival in Patients with High-Risk Hematopoietic Stem Cell Transplant (HSCT)-Associated Thrombotic Microangiopathy (TMA) 

Eculizumab Treatment Improves Survival in Patients with High-Risk Hematopoietic Stem Cell Transplant (HSCT)-Associated Thrombotic Microangiopathy (TMA) 
Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,
Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,

A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,
A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 

Similar presentations

Ads by Google